ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2108

Identification of Four Parameters That Drive the Discordance Between the Patient and Physician Global Assessment in Rheumatoid Arthritis

William Bensen1, Denis Choquette2, Milton F. Baker3, Susan M. Otawa4 and Hayssam Khalil4, 1St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3University of Victoria, Victoria, BC, Canada, 4Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Assessment, patient and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patient (PtGA) and physician (MDGA) global assessment of disease activity are standard outcome measures used to ascertain physician and patient subjective perception of disease activity in rheumatoid arthritis (RA). Given that the PtGA and MDGA measure the same construct from two different perspectives, assessing their discordance may provide valuable insight on patient and physician differences with respect to the relative importance placed on specific disease parameters.

Methods: BioTRAC is an ongoing Canadian registry of patients initiating treatment with infliximab or golimumab as first biologics. PtGA and MDGA were measured at baseline using a 10cm VAS. Using tertiles of the baseline MDGA-PtGA distribution every patient was classified as having higher assessment than the physician (range: -10.0 to -0.5), agreement (range: -0.4 to 1.1) or lower assessment than the physician (range: 1.2 to 8.0).

Results:

841 patients with baseline data for both PtGA and MDGA were included. Among these 623 (74.1%) were female, mean age was 57.0 yrs and mean disease duration was 9.8 yrs. Mean (SD) PtGA and MDGA were 6.1 (2.4) and 6.5 (2.1), respectively, and the mean (SD) PtGA – MDGA was 0.4 (2.4) with a median of 0.3; for 6.4% of the patients the PtGA-MDGA was nil.

Significant differences between patients with lower, equal or higher assessment relative to the physician assessment were identified. When compared to patients with higher PtGA relative to MDGA, patients with lower assessment of their disease activity had lower morning (AM) stiffness, pain, and HAQ-DI but higher SJC (Table 1). AM stiffness, SJC, TJC, and HAQ-DI were highest in patients with PtGA-MDGA agreement. Age, gender, and SJC/TJC ratio were not different for the three groups. Linear regression using backwards selection identified pain (P<0.001), SJC (P<0.001), and HAQ-DI (P=0.056) as independent predictors of PtGA-

Table 1: Patient Baseline Characteristics by Degree of Difference Between MDGA and PtGA

Mean (SD)

Lower

PtGA vs. MDGA1

Higher

PtGA vs. MDGA2

P-Value3

Age: Years

56.9 (13.8)

57.2 (13.2)

0.815

Disease Duration: Years

9.0 (8.3)

10.0 (10.5)

0.478

AM Stiffness: min

62.0 (44.5)

70.7 (43.2)

0.019

Pain: VAS mm

42.0 (22.4)

67.4 (21.2)

<0.001

SJC-28

11.1 (7.0)

9.1 (6.4)

<0.001

TJC-28

12.0 (8.1)

11.4 (7.3)

0.326

SJC/TJC

1.1 (1.1)

1.1 (1.6)

0.805

HAQ-DI

1.42 (0.73)

1.69 (0.65)

<0.001

1 MDGA-PtGA range: 1.2 to 8.0

2  MDGA-PtGA range: -10.0 to -0.5

3  P-Value was assessed with a t-test for independent samples

MDGA.

Conclusion: The relative importance of morning stiffness, pain, HAQ, and SJC in assessing disease activity may be different between patients and physicians. These results have implications for development of assessment tools that better represent both patient and physician perspectives of disease activity.


Disclosure:

W. Bensen,
None;

D. Choquette,
None;

M. F. Baker,
None;

S. M. Otawa,

Janssen Canada Inc,

3;

H. Khalil,

Janssen Canada Inc,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-four-parameters-that-drive-the-discordance-between-the-patient-and-physician-global-assessment-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology